Novartis Gets FDA Breakthrough Therapy Designation for Scemblix
By Pierre Bertrand
Novartis said the U.S. drug regulator decided to expedite the development of Scemblix, to treat adults newly diagnosed with leukemia.
The Swiss pharmaceutical company said the U.S. Food and Drug Administration designated the treatment as a breakthrough therapy for the third time.
Drugs that get designated as breakthrough therapies are those designed to treat serious conditions and that have shown "that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s)," according to the FDA's website.
This latest designation was based off of the Phase III ASC4FIRST study, in which the drug met both of its primary endpoints, the company said.
Novartis will present the full findings of the study at the end of May.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
May 10, 2024 09:42 ET (13:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations